Clinical Trial

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-06-10; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2022-09-01
Trial Details
NCT Number NCT05417971
Lead Sponsor Northside Hospital, Inc.
Conditions Hematologic Malignancy
Enrollment 20 participants
Start Date 2022-08-29
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16